WMIC 2026 | Travel Award
Radioligand Therapy (RLT) Travel Awards
Empowering RLT pioneers with travel grants, visibility, and global platform your research deserves.
DEADLINE APRIL17, 2026
Radioligand Therapy (RLT) represents one of the most impactful and rapidly advancing areas of molecular imaging, spanning discovery, translation, and clinical practice. In the current funding climate, travel support has become a significant barrier for trainees and investigators to share their work, build collaborations, and advance their careers.
While titled around Radioligand Therapy, this program intentionally encompasses the full theranostics lifecycle – from early target discovery and probe design through translation, dosimetry, clinical evaluation, and patient outcomes. In doing so, the awards reinforce theranostics as a core and evolving scientific pillar of WMIC.
More Than Just Travel Support
Financial Support
Career Visibility
Publication
Applicants must be the presenting author of an accepted WMIC 2026 abstract (poster or oral) submitted during the General Abstract period, and must have selected the “RLT Travel Award” option in the Awards section of the abstract submission form.
- Attend WMIC in person; awards are presented on site
- Be an active WMIS member at the time of application
- Trainees and principal investigators are eligible
- Work must focus on Radioligand Therapy and/or Translational Theranostics
- A maximum of two awards will be awarded per lab (per PI).
Each travel award provides support for meeting participation, plus recognition through WMIS/WMIC channels.
- Travel award amount: $1,000 per recipient
- Recognition in the program app + award webpage + on-site signage
The top preclinical and top clinical abstract will be:
- Acknowledged during the Closing Session
- Featured in an editorial in Molecular Imaging and Biology (MIB)
Do I need to attend WMIC 2026 in person?
Yes. Award recipients must attend WMIC in person. Travel Awards are distributed on-site during the congress.
Do I need to be a WMIS member to apply?
Yes. Applicants must be active WMIS members at the time of application.
What types of projects/abstracts are considered “RLT / Translational Theranostics”?
The program is intentionally broad and includes the full translational continuum ranging from:
- Target identification and validation
- Innovation in isotope science
- Radiochemistry and probe design
- Imaging-guided therapy
- Radiobiology and dosimetry
- Predictive biomarkers of radiotherapy response
- Translational and first-in-human studies
How are applications reviewed and selected?
Eligible submissions are reviewed by a scientific advisory group representing expertise across the RLT ecosystem. Selection is based on scientific merit, relevance to RLT/translational theranostics, and overall impact.
Can industry-affiliated applicants apply?
Yes, industry-affiliated applicants may apply if they meet the eligibility criteria. Conflict-of-interest safeguards apply during review.
When will recipients be notified?
Recipients will be notified in mid-June 2026.
If I receive an award but can’t attend WMIC, what happens?
Because awards are presented on-site, recipients who cannot attend in person may forfeit the award. If circumstances change, contact WMIS as soon as possible.
Submit an Abstract
To apply, submit your WMIC abstract by April 17, 2026 and choose “RLT Travel Award” in the Awards section of the submission form.